• Skip to main content
  • Skip to primary sidebar
  • Home
  • News
  • Education
  • Events
  • Interviews
    • Career spotlight
  • Opinion
    • Professional Dilemmas
    • Patient perspective
  • PIPcast
  • Jobs
  • Business Directory

Pharmacy in Practice

EDX/20/1154
Date of prep: December 2020

Prescribing information and
adverse events reporting

For healthcare professionals only

Pharma companies fined £2.3 million for illegal behaviour

9th July 2020 by PIP editor Leave a Comment

 

The Competitions and Markets Authority (CMA) has formally concluded that three pharmaceutical companies took part in an illegal arrangement in relation to the supply of medicine.

 

The investigation by the Competition and Markets Authority into the supply of fludrocortisone, a pharmaceutical drug that is relied upon by thousands of patients, has resulted in fines totalling almost £2.3m and a payment of £8m directly to the NHS.

 

Fludrocortisone is a prescription-only medicine mainly used to treat primary or secondary adrenal insufficiency, commonly known as Addison’s Disease. It is paid for by the NHS and so ultimately by UK taxpayers.

 

Today, the CMA has found that the pharmaceutical companies Amilco and Tiofarma agreed to stay out of the fludrocortisone market so that Aspen could maintain its position as the sole supplier in the UK.

 

In exchange, Amilco received a 30% share of the increased prices that Aspen was able to charge, and Tiofarma was given the right to be the sole manufacturer of the drug for direct sale in the UK.

 

Following the agreement, the price of fludrocortisone supplied to the NHS increased by up to 1800%.

 

All three companies involved in the agreement – Aspen, Tiofarma, and Amilco – have now admitted to taking part in an anti-competitive agreement regarding the supply of fludrocortisone tablets.

 

The CMA has also now levied fines totalling just under £2.3 million for this illegal behaviour.

 

As well as the fines, Aspen approached the CMA last year and agreed to pay the NHS £8 million to help resolve the CMA’s competition concerns in relation to fludrocortisone. This payment has now been made.

 

Find out more on the CMA’s ‘Fludrocortisone acetate tablets’ case page.

 

This circular is being shared under the Open Government Copyright licence.

 

 

Share this:

  • Tweet
  • WhatsApp
  • Telegram
  • Email

Related

Next article  Covid-19 community pharmacy vaccine campaign begins

Filed Under: News Tagged With: CMA

Register for our upcoming webinar and live Q&A

About PIP editor

Pharmacy in Practice is a UK pharmacy publication with its roots in Scotland.

Reader Interactions

Begin the discussion right here Cancel reply

Primary Sidebar

Categories

Follow Us

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Twitter

PIP business directory

Letters to the editor

Letters to the editor

Community pharmacy central to tackling hepatitis C

People can easily go to multiple pharmacies to buy codeine

Should pharmacists be sent to check home medicine cupboards?

Pharmacists are disillusioned, disenfranchised and marginalised

More letters to the editor here...

Blogs

💊 PIP live pharmacy blog

Winter stresses must not ‘destabilise’ general practice

What is it like to depend on medicine to treat endometriosis?

Opinion

Why is pharmacy not integral to government mass vaccination plans?

Pharmacy Covid-19 vaccination involvement is a ‘no-brainer’

The great patient medication returns debacle

CPD Challenges

💊 CPD Challenge: How well do you understand pulmonary embolisms?

💊 CPD Challenge: Prescribing and dispensing clozapine

💊 CPD Challenge: Oral anticoagulants – Dabigatran

More CPD challenges here...

© 2021 · About Pharmacy In Practice · Site mantained by Mike

This site is for healthcare professionals, please confirm you are a healthcare professional to continue.

YES

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
Pharmacy In Practice uses cookies, by continuing to use this site we will assume you are ok with that Find out more.